查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1959910

胜肽类抗生素市场－全球产业规模、份额、趋势、机会、预测：按类型、给药途径、分销管道、地区和竞争格局划分，2021-2031年

Peptide Antibiotics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Route of Administration, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球胜肽类抗生素市场预计将从 2025 年的 53.8 亿美元成长到 2031 年的 81.3 亿美元，复合年增长率达到 7.12%。

这些抗生素由短的氨基酸序列组成，透过破坏细菌细胞膜或干扰关键的细胞内过程发挥抗菌作用。市场成长的主要驱动力是日益严重的全球抗生素抗药性威胁以及对治疗多重抗药性感染疾病的新型有效治疗方法的迫切需求。与传统的小分子药物不同，肽类抗生素具有独特的作用机制，且不易诱导抗药性，这些因素正在推动相关研究的扩展和临床应用。

市场概览
预测期 2027-2031
市场规模：2025年 53.8亿美元
市场规模：2031年 81.3亿美元
复合年增长率：2026-2031年 7.12%
成长最快的细分市场 注射药物
最大的市场 北美洲

儘管存在这些可能性，但市场扩张仍面临许多重大障碍，包括代谢稳定性以及大规模合成的高成本。此外，该产业还面临开发平臺脆弱的问题，限制了后期治疗方案的供应。例如，国际药品製造商协会联合会（IFPMA）在2025年报告称，届时全球临床研发管线中仅有一种针对重点病原体的抗生素候选药物处于III期临床试验阶段。这种缺乏先进候选药物的情况凸显了阻碍该领域发展的持续存在的经济和科学挑战。

市场驱动因素

全球抗菌素抗药性（AMR）的蔓延是全球胜肽类抗生素市场的主要驱动因素。随着细菌病原体不断发展出针对标准小分子药物的防御机制，人们对具有独特作用机制的胜肽类疗法的需求日益增长。这些药物对于应对日益增加的一线治疗无效感染疾病至关重要。世界卫生组织（WHO）于2025年10月发布的《2025年全球抗菌素抗药性监测报告》显示，在2018年至2023年间，超过40%的受监测病原体-抗生素组合的抗药性增加。这一趋势凸显了临床上迫切需要具有细菌膜破坏特性且抗药性风险低的胜肽类药物。世卫组织也报告称，到2025年，全球六分之一的细菌感染疾病将由抗药性病原体引起，这表明这些新型治疗方法具有巨大的市场潜力。

同时，公私部门对抗生素研发投入的增加，透过降低药物研发中固有的财务风险，正在加速市场成长。儘管抗生素合成的高成本和有限的商业性回报历来阻碍了创新，但近期的金融机制正在重振该产业。这些投资使生物技术公司能够帮助早期胜肽类候选药物顺利度过充满挑战的早期临床试验阶段。正如2025年4月发布的CARB-X 2024财年年度报告中所详述，该加速器支持着67%正在进行的针对重点病原体的非传统抗菌疗法I期临床试验计画。这种资金支持对于稳定开发平臺至关重要，并确保先进的胜肽工程技术能够转化为符合严格安全标准且具有商业性可行性的治疗方法。

市场挑战

全球胜肽类抗生素市场受到开发平臺脆弱性的严重限制，导致后期治疗药物供应不足。这种结构性缺陷源自于抗生素领域持续存在的经济困境，复杂的胜肽合成过程和高成本往往超过潜在的市场效益。因此，大型製药公司由于资本投入减少而缩减了业务规模。在此背景下，创新重担转移到了中小型生物技术公司身上，而这些公司往往缺乏将新型肽类候选药物推进到严苛且高成本的后期临床开发阶段所需的财务实力。

投资不足的问题因该细分领域药物研发所需专业科研人才的严重短缺而进一步加剧。根据抗菌药物抗药性产业联盟（AMR Industry Alliance）统计，截至2024年，全球整体仅约有3,000名研究人员积极从事新型抗生素的研发工作。这种熟练人才的短缺直接阻碍了代谢稳定性等技术难题的解决，导致新型肽类疗法的上市进程延缓，市场成长长期停滞。

市场趋势

製药公司和研究机构正越来越多地利用人工智慧演算法和深度学习模型来预测胜肽结构、优化胺基酸序列以降低毒性，并快速识别新型抗菌肽（AMP）。这些技术的融合使得分析传统方法无法处理的大量生物资料集成为可能，从而有效加速了药物发现的早期阶段。例如，研究人员近期应用机器学习技术，透过对古代生物进行蛋白质体学分析来寻找潜在的治疗候选药物。 2025年8月，宾州大学发表了一篇题为《人工智慧从古代微生物中发现新型抗生素》的论文，报告称其人工智慧模型成功地从已灭绝物种的基因组中识别出12,623种潜在的抗菌肽，展现了人工智慧能够揭示的候选物质数量之庞大。

在製造业领域，永续和自动化生产方式正日益普及。特别是，绿色化学溶剂和先进的固相胜肽合成（SPPS）技术的应用旨在减少有害废弃物并提高规模化生产能力。随着对胜肽类药物需求的不断增长，合约研发生产机构（CDMO）正大力投资自动化基础设施，以弥合实验室合成与商业化生产之间的差距。为了顺应这一高产能自动化趋势，产业巨头正在大幅扩大在欧洲的工厂。例如，在2025年3月发布的题为「CordenPharma将在瑞士新建价值超过5亿欧元的胜肽待开发区药物生产基地」的新闻稿中，CordenPharma宣布建设计画一座配备先进自动化设备的新工厂，其SPPS反应器的总容量将超过5000公升。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球胜肽类抗生素市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依类型（非核醣体合成胜肽类抗生素、核醣体合成胜肽类抗生素）
    • 给药途径（注射、口服、外用）
    • 分销通路（医院药局、网路药局、零售药局）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美胜肽类抗生素市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲胜肽类抗生素市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区胜肽类抗生素市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲胜肽类抗生素市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲胜肽类抗生素市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球胜肽类抗生素市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Pfizer Inc.
  • Merck & Co., Inc.
  • AbbVie Inc
  • GSK Plc
  • Sandoz International GmbH
  • The Menarini Group
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • AuroMedics Pharma LLC

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 16968

The Global Peptide Antibiotics Market is projected to grow from USD 5.38 Billion in 2025 to USD 8.13 Billion by 2031, achieving a CAGR of 7.12%. These antibiotics are composed of short amino acid sequences that act as antimicrobial agents by disrupting bacterial membranes or interfering with vital intracellular processes. The market's growth is primarily fueled by the increasing global threat of antimicrobial resistance and the critical need for new treatments effective against multi-drug resistant infections. Unlike traditional small-molecule drugs, peptide antibiotics possess unique mechanisms of action and a reduced likelihood of inducing resistance, factors that are driving their expanded research and clinical adoption.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 5.38 Billion
Market Size 2031USD 8.13 Billion
CAGR 2026-20317.12%
Fastest Growing SegmentInjectable
Largest MarketNorth America

Despite this potential, market expansion faces significant hurdles regarding metabolic stability and the high costs associated with large-scale synthesis. The industry also contends with a weak developmental pipeline that restricts the availability of late-stage therapeutic options. For instance, the International Federation of Pharmaceutical Manufacturers and Associations reported in 2025 that the global clinical pipeline included only one antibiotic candidate in Phase III trials aimed at critical priority pathogens. This shortage of advanced candidates emphasizes the enduring economic and scientific challenges that continue to impede the sector's progress.

Market Driver

The rising global prevalence of antimicrobial resistance (AMR) serves as the primary driver for the Global Peptide Antibiotics Market. As bacterial pathogens develop defenses against standard small-molecule drugs, the demand for peptide-based therapeutics with unique modes of action has intensified. These agents are crucial for treating the increasing number of infections that fail to respond to first-line therapies. The World Health Organization's 'Global Antibiotic Resistance Surveillance Report 2025', released in October 2025, noted that resistance increased in over 40% of monitored pathogen-antibiotic combinations between 2018 and 2023. This trend highlights the urgent clinical need for peptides that disrupt bacterial membranes with a lower risk of resistance, while the WHO also reported in 2025 that one in six bacterial infections globally involved resistant pathogens, illustrating the vast market potential for these new interventions.

Concurrently, increased public and private funding for antibiotic R&D is accelerating market growth by alleviating the financial risks inherent in drug development. Although the high costs and limited commercial returns of antibiotic synthesis have historically stifled innovation, recent financial mechanisms have revitalized the industry. These investments allow biotechnology firms to progress early-stage peptide candidates through the difficult initial phases of clinical trials. As stated in CARB-X's '2024 Annual Report' from April 2025, the accelerator has supported 67% of the active Phase 1 clinical pipeline for non-traditional antibacterial therapeutics targeting critical priority pathogens. This financial backing is essential for stabilizing the developmental pipeline and ensuring that advanced peptide engineering technologies can result in commercially viable therapies that meet rigorous safety standards.

Market Challenge

The Global Peptide Antibiotics Market is substantially hindered by a fragile developmental pipeline that limits the supply of late-stage therapeutics. This structural weakness arises from persistent economic difficulties within the antibiotic sector, where the high costs of complex peptide synthesis and clinical trials often outweigh potential market returns. Consequently, capital investment has declined, leading major pharmaceutical companies to reduce their participation. This environment shifts the burden of innovation to smaller biotechnology firms, which frequently lack the financial resilience needed to advance novel peptide candidates through the rigorous and expensive stages of advanced clinical development.

This lack of investment is compounded by a critical shortage of the specialized scientific workforce needed to drive discovery in this niche field. The AMR Industry Alliance reported that in 2024, there were only approximately 3,000 researchers globally actively focused on developing new antibiotics. This scarcity of skilled human capital directly impedes the resolution of technical issues such as metabolic stability, thereby delaying the introduction of new peptide therapies and causing prolonged stagnation in market growth.

Market Trends

Pharmaceutical companies and research institutions are increasingly utilizing AI algorithms and deep learning models to predict peptide structures, optimize amino acid sequences to lower toxicity, and accelerate the identification of novel antimicrobial peptides (AMPs). Integrating this technology enables developers to analyze immense biological datasets that are impossible to process via traditional screening methods, effectively revitalizing the early-stage discovery pipeline. Highlighting this capability, researchers recently applied machine learning to examine the proteomes of ancient organisms for hidden therapeutic candidates. In August 2025, the University of Pennsylvania reported in the article 'AI uncovers new antibiotics in ancient microbes' that their AI model successfully identified 12,623 potential antimicrobial peptides in the genomes of extinct species, demonstrating the vast volume of candidates AI can reveal.

In the manufacturing sector, there is a shift toward sustainable and automated production methods, particularly utilizing green chemistry solvents and advanced Solid-Phase Peptide Synthesis (SPPS) to reduce hazardous waste and enhance scalability. As the demand for peptide therapeutics rises, Contract Development and Manufacturing Organizations are investing heavily in automated infrastructure to bridge the gap between laboratory synthesis and commercial-scale production. Demonstrating this trend toward high-capacity automation, major industry players are significantly expanding their European facilities. For example, CordenPharma announced in a March 2025 press release titled 'CordenPharma Builds >€500m Switzerland Peptide Greenfield Site' its plans to construct a new facility featuring advanced automation with a total SPPS reactor capacity exceeding 5,000 liters.

Key Market Players

  • Pfizer Inc.
  • Merck & Co., Inc.
  • AbbVie Inc
  • GSK Plc
  • Sandoz International GmbH
  • The Menarini Group
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • AuroMedics Pharma LLC

Report Scope

In this report, the Global Peptide Antibiotics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Peptide Antibiotics Market, By Type

  • Non-Ribosomal Synthesized Peptide Antibiotics
  • Ribosomal Synthesized Peptide Antibiotics

Peptide Antibiotics Market, By Route of Administration

  • Injectable
  • Oral
  • Topical

Peptide Antibiotics Market, By Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy & Retail Pharmacy

Peptide Antibiotics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Peptide Antibiotics Market.

Available Customizations:

Global Peptide Antibiotics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Peptide Antibiotics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Non-Ribosomal Synthesized Peptide Antibiotics, Ribosomal Synthesized Peptide Antibiotics)
    • 5.2.2. By Route of Administration (Injectable, Oral, Topical)
    • 5.2.3. By Distribution Channel (Hospital Pharmacy, Online Pharmacy & Retail Pharmacy)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Peptide Antibiotics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Peptide Antibiotics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Peptide Antibiotics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Peptide Antibiotics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel

7. Europe Peptide Antibiotics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Peptide Antibiotics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Peptide Antibiotics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Peptide Antibiotics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Peptide Antibiotics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Peptide Antibiotics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Peptide Antibiotics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Peptide Antibiotics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Peptide Antibiotics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Peptide Antibiotics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Peptide Antibiotics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Peptide Antibiotics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Peptide Antibiotics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Peptide Antibiotics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Peptide Antibiotics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Peptide Antibiotics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. South America Peptide Antibiotics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Peptide Antibiotics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Peptide Antibiotics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Peptide Antibiotics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Peptide Antibiotics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Pfizer Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Merck & Co., Inc.
  • 15.3. AbbVie Inc
  • 15.4. GSK Plc
  • 15.5. Sandoz International GmbH
  • 15.6. The Menarini Group
  • 15.7. Novartis AG
  • 15.8. Teva Pharmaceutical Industries Ltd.
  • 15.9. AuroMedics Pharma LLC

16. Strategic Recommendations

17. About Us & Disclaimer